Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Related Posts
Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford[...]
Cappelletti M, Short D, Morselli M, Pellegrini M, Johnson MR, Afshar Y, Kallapur SG, Presicce P. Protocol for isolating amnion cells from human and non-human[...]
Ghafari-Saravi A, Haussmann A, Wu J, Cheng K. Treatment of severe perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with efgartigimod. JAAD Case Rep. 2024 Mar 15;47:68-71. doi:[...]